|
CA1333363C
(en)
|
1988-01-19 |
1994-12-06 |
Judah Folkman |
Angiogenesis inhibitor comprising fumagillin
|
|
ES2053890T3
(es)
|
1988-09-01 |
1994-08-01 |
Takeda Chemical Industries Ltd |
Agente inhibidor de la angiogenesis.
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
US9707302B2
(en)
*
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
EP2007733B1
(en)
|
2006-04-03 |
2016-05-25 |
MSD Italia S.r.l. |
Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
|
|
AR064777A1
(es)
|
2007-01-10 |
2009-04-22 |
Inst Di Reserche D Biolog Mole |
Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
KR20100102607A
(ko)
|
2007-11-12 |
2010-09-24 |
바이파 사이언스 인코포레이티드 |
Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
|
|
CN103169973A
(zh)
|
2007-11-12 |
2013-06-26 |
彼帕科学公司 |
使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
|
|
CN101959429B
(zh)
|
2008-01-08 |
2014-09-10 |
阿克塞利亚制药公司 |
抗微生物肽系统的激动剂
|
|
JP5989965B2
(ja)
|
2008-01-08 |
2016-09-07 |
メルク シャープ エンド ドーム リミテッド |
２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
US20120130144A1
(en)
*
|
2009-02-04 |
2012-05-24 |
Bipar Sciences, Inc. |
Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
WO2011153383A1
(en)
|
2010-06-04 |
2011-12-08 |
Bipar Science, Inc. |
Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
|
|
DK3327148T3
(da)
|
2010-06-18 |
2021-04-12 |
Myriad Genetics Inc |
Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle
|
|
ES2704303T3
(es)
|
2010-08-24 |
2019-03-15 |
Dana Farber Cancer Inst Inc |
Procedimientos para la predicción de una respuesta contra el cáncer
|
|
CA2742342A1
(en)
|
2011-02-12 |
2012-08-12 |
Baylor Research Institute |
Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
ES2658867T3
(es)
|
2012-06-07 |
2018-03-12 |
Institut Curie |
Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
|
|
US9738915B2
(en)
|
2012-12-07 |
2017-08-22 |
Merck Sharp & Dohme Corp. |
Biocatalytic transamination process
|
|
US9580407B2
(en)
|
2012-12-07 |
2017-02-28 |
Merck Sharp & Dohme Corp. |
Regioselective N-2 arylation of indazoles
|
|
US9850542B2
(en)
|
2013-03-04 |
2017-12-26 |
Board Of Regents, The University Of Texas System |
Gene signature to predict homologous recombination (HR) deficient cancer
|
|
AR095363A1
(es)
|
2013-03-15 |
2015-10-14 |
Genentech Inc |
Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
EP3080292B1
(en)
|
2013-12-09 |
2022-02-02 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
|
|
EP3094752A4
(en)
|
2014-01-16 |
2017-08-16 |
Clovis Oncology, Inc. |
Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
|
|
WO2015116868A2
(en)
|
2014-01-29 |
2015-08-06 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
US10238630B2
(en)
|
2014-05-28 |
2019-03-26 |
Eisai R&D Management Co., Ltd. |
Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
US20160160294A1
(en)
|
2014-12-08 |
2016-06-09 |
Tesaro |
Methods and materials for predicting response to niraparib
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
EA201792184A1
(ru)
|
2015-04-01 |
2018-04-30 |
Анаптисбайо, Инк. |
Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
|
|
EP3288982A1
(en)
|
2015-04-28 |
2018-03-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
|
HK1251474A1
(zh)
|
2015-06-08 |
2019-02-01 |
豪夫迈‧罗氏有限公司 |
使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
|
|
EP4257134A3
(en)
|
2015-06-25 |
2024-01-24 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
EP3337467B1
(en)
|
2015-08-20 |
2020-12-09 |
Ipsen Biopharm Ltd. |
Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
|
|
CN108883115A
(zh)
|
2015-10-26 |
2018-11-23 |
麦迪韦逊科技有限责任公司 |
用parp抑制剂治疗小细胞肺癌
|
|
RU2740849C2
(ru)
|
2016-02-15 |
2021-01-21 |
Астразенека Аб |
Способ, включающий фиксированное дробное дозирование цедираниба
|
|
KR20230042136A
(ko)
|
2016-06-29 |
2023-03-27 |
테사로, 인코포레이티드 |
난소암의 치료 방법
|
|
CN110087730B
(zh)
*
|
2016-09-27 |
2023-03-28 |
百济神州(苏州)生物科技有限公司 |
使用包含parp抑制剂的组合产品治疗癌症
|
|
CA3041684C
(en)
|
2016-11-01 |
2023-09-26 |
Anaptysbio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
SG11201903867YA
(en)
|
2016-11-01 |
2019-05-30 |
Anaptysbio Inc |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
MX2019008208A
(es)
|
2017-01-09 |
2019-12-11 |
Tesaro Inc |
Métodos para tratar el cáncer con anticuerpos anti-tim-3.
|
|
PT3565844T
(pt)
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
BR112019020211A2
(pt)
|
2017-03-27 |
2020-04-22 |
Tesaro, Inc. |
composições de niraparib
|
|
KR20190130625A
(ko)
|
2017-03-27 |
2019-11-22 |
테사로, 인코포레이티드 |
니라파립 제제
|
|
KR102582624B1
(ko)
|
2017-04-24 |
2023-09-22 |
테사로, 인코포레이티드 |
니라파립의 제조 방법
|
|
EP3615572A1
(en)
|
2017-04-27 |
2020-03-04 |
Tesaro Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
TWI879716B
(zh)
|
2017-05-09 |
2025-04-11 |
美商提薩羅有限公司 |
治療癌症的組合療法
|
|
AU2018270112A1
(en)
|
2017-05-18 |
2019-12-12 |
Tesaro, Inc. |
Combination therapies for treating cancer
|
|
WO2019005762A1
(en)
|
2017-06-26 |
2019-01-03 |
Abbvie Inc. |
TREATMENT OF NON-SMALL CELL LUNG CANCER
|
|
KR20250016494A
(ko)
|
2017-09-26 |
2025-02-03 |
테사로, 인코포레이티드 |
니라파립 제제
|
|
EP3697442A4
(en)
|
2017-09-30 |
2021-07-07 |
Tesaro, Inc. |
COMBINATION THERAPIES FOR TREATMENT OF CANCER
|
|
SG11202002499TA
(en)
|
2017-10-06 |
2020-04-29 |
Tesaro Inc |
Combination therapies and uses thereof
|
|
SG11202006147SA
(en)
|
2017-12-27 |
2020-07-29 |
Tesaro Inc |
Methods of treating cancer
|
|
AU2019215450A1
(en)
|
2018-02-05 |
2020-08-27 |
Tesaro, Inc |
Pediatric niraparib formulations and pediatric treatment methods
|
|
EA201992594A1
(ru)
|
2018-03-26 |
2020-03-20 |
Тесаро, Инк. |
Комбинированные терапии для лечения рака
|
|
US11970530B2
(en)
|
2020-08-13 |
2024-04-30 |
Astrazeneca Ab |
Methods of treating homologous recombination deficient cancer
|